Active surveillance of renal masses: An analysis of growth kinetics and clinical outcomes stratified by radiological characteristics at diagnosis

International Braz J Urol

Volumn 40, Issue 5, 2014, Pages 627-636

  Dorin, Ryan ^a   Jackson, Max ^a   Cusano, Antonio ^a   Haddock, Peter ^a   Kiziloz, Halil ^a   Meraney, Anoop ^a   Shichman, Steven ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Angiomyolipoma; Chronotherapy; Kinetics; Watchful waiting

Indexed keywords

EID: 84920099630     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2014.05.07     Document Type: Article

References (19)

1. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK: Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006; 98: 1331-4.
2. Chiu Y, Chiu AW: Renal preservation therapy for renal cell carcinoma. Int J Surg Oncol. 2012; 2012: 123596.
3. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG: The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006; 175: 425-31.
4. Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, et al.: Contemporary management of small renal masses. Eur Urol. 2011; 60: 501-15.
5. Cairns P: Renal cell carcinoma. Cancer Biomark. 2010; 9: 461-73
6. Mues AC, Landman J: Small renal masses: current concepts regarding the natural history and reflections on the American Urological Association guidelines. Curr Opin Urol. 2010; 20: 105-10.
7. AUA clinical guidelines: guideline for management of the clinical stage 1 renal mass. 2009. pp. 1-76.
8. Thomas AA, Campbell SC: Small renal masses: toward more rational treatment. Cleve Clin J Med. 2011; 78: 539-47.
9. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK: Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007; 109: 1763-8.
10. Sooriakumaran P, Gibbs P, Coughlin G, Attard V, Elmslie F, Kingswood C, et al.: Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010; 105: 101-6.
11. Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, et al.: Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009; 182: 41-5.
12. Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, et al.: Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011; 59: 863-7.
13. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, et al.: Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012; 118: 997-1006.
14. Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L.: Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol. 2012; 188: 2063-71.
15. Mucksavage P, Ramchandani P, Malkowicz SB, Guzzo TJ: Is ultrasound imaging inferior to computed tomography or magnetic resonance imaging in evaluating renal mass size? Urology. 2012; 79: 28-31.
16. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J: Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995; 197: 589-97.
17. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG: Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009; 115: 2844-52.
18. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, et al.: Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011; 60: 39-44.
19. Volpe A, Cadeddu JA, Cestari A, Gill IS, Jewett MA, Joniau S, et al.: Contemporary management of small renal masses. Eur Urol. 2011; 60: 501-15.